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Background and Purpose—Microbleeds (MBs) are commonly observed in Alzheimer disease. A minority of patients has
multiple MBs. We aimed to investigate associations of multiple MBs in Alzheimer disease with clinical and MRI
characteristics and cerebrospinal fluid biomarkers.
Methods—Patients with Alzheimer disease with multiple (8) MBs on T2*-weighted MRI were matched for age, sex, and
field strength with patients with Alzheimer disease without MBs on a 1:2 basis. We included 21 patients with multiple
MBs (737 years, 33% female) and 42 patients without MBs (727 years, 38% female). Mini-Mental State
Examination was used to assess dementia severity. Cognitive functions were assessed using neuropsychological tests.
Medial temporal lobe atrophy (0 to 4), global cortical atrophy (0 to 3), and white matter hyperintensities (0 to 30) were
assessed using visual rating scales. In a subset, apolipoprotein E genotype and cerebrospinal fluid amyloid  1-42, total
 and  phosphorylated at threonine 181 were determined.
Results—Patients with multiple MBs performed worse on Mini-Mental State Examination (multiple MB: 177; no MB:
224, P0.05) despite similar disease duration. Atrophy was not related to presence of MBs, but patients with multiple
MBs had more white matter hyperintensities (multiple MB: 8.84.8; no MB: 3.23.6, P0.05). Adjusted for age, sex,
white matter hyperintensities, and medial temporal lobe atrophy, the multiple MB group additionally performed worse
on Visual Association Test object naming and animal fluency. Patients with multiple MBs had lower cerebrospinal fluid
amyloid  1-42 levels (30761) than patients without MBs (505201, P0.05). Adjusted for the same covariates, total
, and  phosphorylated at threonine 181 were higher in the multiple MB group.
Conclusion—Microbleeds are associated with the clinical manifestation and biochemical hallmarks of Alzheimer disease,
suggesting possible involvement of MBs in the pathogenesis of Alzheimer disease. (Stroke. 2009;40:3455-3460.)
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Alzheimer disease (AD) is the main cause of dementia inthe elderly. The pathological hallmarks are neuritic
plaques (amyloid ) and neurofibrillary tangles ().1 Further-
more, in 70% to 98% of patients with AD, intravascular
amyloid  deposition is found at autopsy.2 Atrophy, espe-
cially of the medial temporal lobes, constitutes the radiolog-
ical hallmark of AD on MRI. In addition, white matter
hyperintensities (WMH) have been shown to be more
prevalent in patients with AD than in control subjects.
Microbleeds (MBs) can be observed on T2*-weighted
gradient-echo MRI. Histologically, they represent hemosid-
erin-laden macrophages resulting from leakage from cerebral
small vessels.3–5
Recent findings indicate that MBs in the general elderly
population are relatively common and are even more fre-
quently observed in patients with AD.6–9 In our memory
clinic population, prevalence of one or more MBs in patients
with AD was 18%.10 Among those patients, the majority had
only one or a few MBs. However, a subgroup of patients with
AD shows many MBs. Lobar MBs in corticosubcortical
locations with a posterior predilection are thought to be an
expression of underlying bleeding-prone cerebral amyloid
angiopathy (CAA), especially in patients with AD.6,9,11,12
Because CAA has been related previously to low amyloid
levels in cerebrospinal fluid (CSF), presumably resulting
from increased intravascular amyloid deposition,13 we hy-
pothesized that amyloid levels in CSF would be reduced in
patients with AD with multiple MBs as a result of intravas-
cular amyloid pathology.
The occurrence of MBs seems to increase with age and is
believed to coincide with hypertension,14 ischemic and hem-
orrhagic stroke, lacunes, and the extent of white matter
disease.15 MBs have been associated with cognitive decline in
patients with stroke and subcortical vascular dementia and in
the general elderly population.16–19 In AD, however, the
clinical significance of MBs remains elusive.6,10,15,20
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Former studies finding no correlation of MBs with clinical
manifestation included many patients with one or just a few
MBs. We took a proof-of-principle approach by comparing
patients with AD with many MBs with patients with AD without
any MBs maximizing possible differences between patient
groups. We aimed to investigate the associations of multiple
MBs in patients with AD with clinical, neuropsychological, and
MRI characteristics and levels of CSF biomarkers.
Materials and Methods
Patients
From our database of patients who underwent dementia screening at
the Alzheimer Center of the VU University Medical Center Amster-
dam memory clinic, we retrospectively reviewed presence and
number of MBs in patients with a diagnosis of probable AD visiting
between May 2001 and July 2008 (n427). Of these, 350 patients
(82%) had no MBs and 67 patients (18%) had one or more MBs
present on baseline T2*-weighted gradient-echo imaging. For the
current study, we selected patients with 8 MBs. This cutoff was
specified in advance before any statistical analysis was performed
and resulted in 21 patients, representing the 5% of patients with AD
with the most severe MB burden (multiple MB group; age 737
years, 33% female). The patients were matched on a 1:2 basis for
age, sex, and MRI field strength with patients with AD without any
MBs. These “control” patients with AD without MBs were selected
to have complete data of interest (no MB group: n42; age 727
years, 38% female). All patients underwent standardized dementia
screening, including medical history, physical, neurological, and
neuropsychological examination. Patients were considered as having
arterial hypertension, diabetes mellitus, or hypercholesterolemia if
they had a known history of the disease or were receiving drug
treatment. Furthermore, screening involved MRI and routine labo-
ratory examinations. Diagnoses of probable AD were made in a
multidisciplinary consensus meeting according to the clinical criteria
of the National Institute of Neurological Disorders and Stroke–Alz-
heimer’s Disease and Related Disorders Association.1 The level of
education was classified using the system of Verhage, ranging from
1 (low) to 7 (high).21 The study was approved by the ethical review
board of the VU University Medical Center and all subjects gave
written informed consent.
Neuropsychological Assessment
The neuropsychological test battery was designed to screen the major
cognitive functions. Two experienced neuropsychologists were re-
sponsible for testing. All testing was done on the same day as MRI
scanning as part of our screening routine, except for 3 patients, who
were tested within 2 months of scanning. Dementia severity was
assessed using the Mini-Mental State Examination (MMSE).22 For
memory, the Visual Association Test (VAT) was used.23 Patients are
shown cue cards with an object and association cards with the
previously seen object plus an interacting object and are asked to
name them. Subsequently, the cue cards are shown without delay and
patients are asked to recall the now missing interacting objects (score
0 to 12). VAT object naming was used as a measure for language (0
to 12). Language functions were additionally assessed using category
fluency, in which patients have to produce as many animals as
possible in a timespan of 60 seconds. In addition, the Trail Making
Test was used.24 The simple Part A provides a measure of psychomo-
tor speed. It requires the connection by pencil of numbers (1 to 20)
positioned randomly on a sheet of paper. The more complex Part B
requires patients to alternate between numbers and letters (eg,
1–A–2–B–3–C–. . .) and was used to evaluate executive functioning.
For both conditions, the time required for completion is recorded.
Additionally, digit span (forward and backward) was used to assess
working memory. Ongoing efforts to optimize the neuropsycholog-
ical screening protocol resulted in a slightly varying content of the
neuropsychological battery over the years. As a result, availability of
the data varied per test from 43 patients on the Trail Making Test B
test, digit span forward and backward (n56), Trail Making Test A
(n57), VAT naming (n58), animal fluency (n59), MMSE
(n60), and VAT (n61).
MRI Protocol
The majority of scans (14 in the multiple MB group and 28 in the no
MB group) were obtained on a 1.0-T scanner (Magnetom Impact;
Siemens, Erlangen, Germany). Twenty-one scans (7 in the multiple
MB group and 14 in the no MB group) were obtained on a 1.5-T
platform (Siemens Sonata Syngo [n17] or Siemens Avanto [n4]).
Scan protocol included (1) axial T2*-weighted gradient-echo images
for MB detection (19 to 23 slices, field of view 250 mm, matrix
256192 to 256, slice thickness: 5 mm, interslice gap: 1 to 1.5 mm,
repetition time: 415 to 800 ms, echo time: 22 to 25 ms, flip angle 15°
to 20°); (2) coronal T1-weighted 3-dimensional magnetization-
prepared rapid acquisition gradient-echo volumes (single slab, 160 to
176 sections; matrix size 256192 to 256; field of view
250250 mm; voxel size 111.5 mm; repetition time 2700 ms,
echo time 5.2 to 7 ms, TI 300 to 950 ms; flip angle 8° to 15°); (3);
axial 2-dimensional fluid-attenuated inversion recovery (field of
view 250 mm, matrix 256184 to 256, slice thickness 5.0 mm,
interslice gap 1.5 mm, echo time 89 to 108 ms, repetition time 9000
ms, TI 2200 to 2500 ms, and flip angle 150°/180°); and (4) axial
T2-weighted turbo spin echo (19 to 21 slices, field of view 250 mm,
matrix 512512, slice thickness 4 to 5 mm, interslice gap 1 mm, echo
time 114 to 199 ms, repetition time 4590 to 5775 ms, flip angle 180°).
MRI Assessment
MRI rating was performed blinded to the patients’ clinical data. MBs
were defined as rounded hypointense homogeneous foci up to 10 mm
in size in the brain parenchyma on T2*-weighted images. Lesions in
sulci possibly representing flow voids from pial vessels and sym-
metrical lesions in the basal ganglia, supposedly representing iron or
calcium deposits, were excluded. Hyposignals inside a lesion com-
patible with an infarct were not counted as MBs, but regarded to be
probable hemorrhagic transformations. Cavernous angiomas were
not taken into account. MBs were counted in 4 lobar regions: frontal,
parietal, temporal, and occipital and in 2 nonlobar regions: basal
ganglia (including thalamus) and infratentorial. In addition, on the
fluid-attenuated inversion recovery sequence WMH were assessed
using the age-related white matter change scale.25 The age-related
white matter change scale has scores from 0 to 3 (none, punctuate,
early confluent, and confluent) given in 5 regions, each left and right,
adding up to a total range from 0 to 30. In addition, the presence of
large-vessel and lacunar infarcts was assessed. Large-vessel infarcts
were rated as present or absent based on hyperintensity of the lesion
on both fluid-attenuated inversion recovery and T2-weighted se-
quences. Lacunar infarcts were defined as deep lesions from 3 to
15 mm with low signal on fluid-attenuated inversion recovery and T1
sequences and high signal on T2-weighted images. Lacunar infarcts
were scored as present or absent. Furthermore, 2 widely used visual
rating scales for the assessment of atrophy were used. Medial
temporal lobe atrophy (MTA) was rated using a 5-point rating scale
(0 to 4) using oblique reconstructions of the magnetization-prepared
rapid acquisition gradient-echo volume sequences perpendicular to
the long axis of the hippocampus.26 In the analysis, the average MTA
score for the left and right side was used. Global cortical atrophy was
assessed on the fluid-attenuated inversion recovery sequence. The
global cortical atrophy scale ranges from 0 to 3.27 On both scales
maximal atrophy is represented by the highest score.
Apolipoprotein E Genotyping
DNA was isolated from 10 mL of ethylenediaminetetra-acetic
acid/blood and was available from 55 of 63 patients (87%). apoli-
poprotein E (APOE) genotype was determined with the light cycler
APOE mutation detection method (Roche Diagnostics GmbH,
Mannheim, Germany). Patients were categorized according to APOE
4 status (noncarriers, heterozygous and homozygous).
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CSF Analysis
In a subset of patients 51 of 63 patients (81%), CSF was obtained by
lumbar puncture between the L3/L4 or L4/L5 intervertebral space,
using a 25-gauge needle, and collected in 10-mL polypropylene
tubes. Within 2 hours, CSF samples were centrifuged at 1800 g for
10 minutes at 4°C. A small amount of CSF was used for routine
analysis, including total cells (leukocytes and erythrocytes), total
protein, and glucose. CSF was aliquoted in polypropylene tubes of
0.5 or 1 mL and stored at 80°C until further analysis. CSF
amyloid-1-42 (A42), total  () and  phosphorylated at threonine
181 (p-181) were measured with Innotest sandwich enzyme-linked
immunosorbent assay as described previously.28 Because the manu-
facturer does not supply controls, the performance of the assays was
monitored with pools of surplus CSF specimens. In the study period,
multiple specimens with various concentrations, which were in-
cluded in 7 to 18 runs, have been used for this purpose. The
interassay coefficients of variation were (meanSD) 11.3%4.9%
for A42; 9.3%1.5% for  and 9.42.5 for p-181. The team
involved in the CSF analysis was not aware of the clinical diagnosis.
Statistical Analysis
For statistical analysis, SPSS 14.0 for Windows (Chicago, Ill) was
used. Categorical data were analyzed by 2 tests. Comparison
between groups for continuous variables was executed by Student t
tests. Analysis of variance as used to adjust for age, sex, WMH, and
MTA. We used logistic regression to investigate the association
between MBs and APOE 4 status adjusted for age, sex, WMH, and
MTA. The correlation between number of MBs and MMSE was
investigated using Spearman correlation coefficient. Significance
was set at P0.05.
Results
In the group of 21 patients with multiple MBs, the total
number of MBs was 491 with a median of 15 MBs (range, 8
to 104). Lobar locations accounted for 94% of the total
number of MBs. Percentage of total MB count per lobe was:
temporal 32%, parietal 24%, occipital 19%, and frontal 19%.
Only 6% of all detected MBs were in nonlobar locations with
4% in the basal ganglia and thalamus and 2% in infratentorial
regions. Eleven patients in the multiple MB group (52%) had
strictly lobar MBs (Figure 1). Six patients (29%) had a few
nonlobar MBs next to mainly lobar MBs, 3 patients (14%)
had comparable numbers of nonlobar and lobar MBs,
whereas only one patient (5%) presented more nonlobar than
lobar MBs.
MRI characteristics, medical history, and medication use
are shown in Table 1. Patients with multiple MBs showed
more severe WMH than those without MBs (P0.001). The
presence of lacunar or large-vessel infarcts did not differ
between groups. No difference between groups regarding
atrophy (global cortical or medial temporal lobe) was found.
There was no difference in disease duration, level of educa-
tion, or medical history between groups. Patients with mul-
tiple MBs more often used antiplatelet medication, whereas
there were no differences in other medications.
Neuropsychological and laboratory results are shown in
Table 2. Patients with multiple MBs had lower MMSE than
patients with AD without MBs (177 versus 224,
P0.005). Furthermore, within the group of patients with
multiple MBs only, we found a correlation between the total
number of MBs and MMSE (Spearman r0.47; P0.05;
Figure 2) with more MBs being associated with lower MMSE
scores. After removal of one outlier with a MMSE of 2 and 38
MBs, the correlation remained of moderate strength, although
significance was lost (Spearman r0.38, P0.05). Unad-
justed, there was no group difference for any of the neuro-
psychological tests. After adjustment for age, sex, MTA, and
WMH, patients with multiple MBs additionally performed
worse on animal fluency, VAT object naming, and digit span
(forward and backward) than the group without MBs
(P0.05). There were no associations between age or sex and
any of the neuropsychological measures. Medial temporal
lobe atrophy was associated with lower VAT memory scores
(Spearman r0.26, P0.05), but there were no associa-
tions with WMH.
Patients with multiple MBs had lower CSF levels of A42
than patients without MBs in univariate analysis (P0.01).
Adjusted for age, sex, MTA, and WMH, patients with
multiple MBs additionally had higher levels of CSF  and
p-181. The aforementioned covariates had no univariate
association with CSF A42 levels. CSF levels of  and p181,
however, were both associated with WMH (Spearman
r0.36, P0.01 and Spearman r0.34, P0.05, respec-
tively) and MTA (Spearman r0.30, P0.05 and Spear-
man r0.28, P0.05, respectively), albeit in the counter-
intuitive direction as higher CSF p levels were observed in
patients with relatively little MTA and WMH.
Patients with multiple MBs were more often homozygous
for APOE 4 (31% versus 17%), although this difference was
not significant (P0.55). When we used logistic regression to
adjust for age, sex, MTA, and WMH, we found that homozy-
gous APOE 4 carriers had an increased risk to have multiple
MBs (OR [95% CI], 16 [0.9 to 276]), almost reaching
significance. After removing 4 patients with multiple deep
Figure 1. Example of axial T2*-weighted gradient echo image of
a patient with multiple MBs. Multiple MBs in the occipital and
temporal lobes, mainly on corticosubcortical junctions, with the
left side more affected. The MBs were strictly lobar in location,
suspect for probable CAA.
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MBs from analysis, we found an even higher OR of 19 (CI,
1.0 to 377; P0.05). On visual inspection, we found that all
homozygous APOE 4 carriers in the multiple MB group had
no or only very little WMH (age-related white matter change
score 4). There was no association between heterozygous
APOE 4 carriership and multiple MBs (OR [95% CI], 1.6
[0.1 to 19]).
Discussion
In this proof-of-principle case–control study, we showed the
relationship between multiple MBs and more pronounced
impairment in a number of cognitive domains. Moreover, we
found that multiple MBs were associated with lower CSF
levels of A42 and higher levels of  and p-181. Although
MBs were associated with more severe WMH, this did not
explain the more pronounced cognitive decline or abnormal
CSF biomarker levels. Furthermore, our findings could not be
explained by longer disease duration, level of education, or
more severe atrophy.
We found an association of multiple MBs with lower CSF
A42, suggesting a direct link between MBs and amyloid-,
one of the key proteins involved in AD. A postmortem study
showed a relationship between the severity of CAA and lower
A42 levels, which could not be explained by amyloid plaque
or tangle burden.13 The authors hypothesized that low levels
of A42 may reflect increased deposition of amyloid  not
only in plaques, but also in cerebral vessels. Accumulation of
Alzheimer-related amyloid pathology in the vessels may lead
to reduced vessel wall integrity, which in turn may result in
MBs. Alternatively, the more abnormal CSF levels may have
been caused indirectly through vascular risk factors and
associated WMH.29 This seems unlikely, however, because
results remained unchanged after adjustment for WMH.
Moreover, when we inspected the univariate associations
between CSF levels of p and WMH, we found that patients
with higher (ie, more abnormal) p 181 levels had less
WMH. A possible explanation for this seemingly counterin-
tuitive finding could be that less WMH implies more pure AD
associated with more abnormal Alzheimer biomarkers. The
combination of high CSF  levels and low-grade periventric-
ular WMH has been described before in patients with mild
cognitive impairment converting to AD.30 We therefore feel
that the association between MBs and  after adjustment for
WMH provides additional support for the notion that MBs
may have a role in the pathogenesis of AD.
Earlier studies reporting on prevalence of MBs in AD (with
prevalences ranging from 17% to 32%)6,7,10,12,15,20 were not
able to show any relationship between MB occurrence and
cognitive performance. In these studies, most patients had
only one or a few MBs. We reasoned that having one or only
a few MBs is not sufficient for any measurable clinical effect.
Therefore, we took a different approach by selecting the 5%
of patients with AD with the most severe MB burden and
comparing these with patients with AD without any MBs. In
Table 1. MRI Characteristics, Medical History, and Medication
Variable
AD 8
MBs (n21)
AD No
MBs (n42)
MRI characteristics
MBs 2424 0
ARWMC score 8.84.8 3.23.6*
Lacunar infarcts 5 (24%) 6 (14%)
Large-vessel infarcts 2 (3%) 1 (2%)
Global cortical atrophy score 1.10.8 1.10.7
MTA score 2.00.9 1.60.9
Medical history
Level of education (1–7)† 4.51.7 5.11.2
Duration of symptoms, years 33 32
Hypertension 6 (29%) 16 (38%)
Stroke or transient ischemic attack 3 (14%) 2 (5%)
Peripheral or cardiac vasculopathy 2 (10%) 6 (14%)
Diabetes mellitus 2 (10%) 3 (7%)
Hypercholesterolemia 0 (0%) 3 (7%)
Medication
Nonsteroidal anti-inflammatory drugs 0 (0%) 1 (2%)
Anticoagulation 0 (0%) 0 (0%)
Antiplatelet medication 6 (29%) 7 (17%)*
Data are represented as no. of patients with the variable present (%) or
meanSD.
*P0.01.
†Level of education according to Verhage.
ARWMC indicates age-related white matter changes.
Table 2. Neuropsychology and Laboratory Results
Variable
AD 8
MBs
(n21)
AD No
MBs
(n42) Unadjusted Adjusted*
Neuropsychological
data
MMSE score 177 224 § §
VAT 44 64 †
VAT object naming 103 121 §
Animal fluency 116 135 ‡
Trail Making Test A 12778 9788
Trail Making Test B 401335 331251
Digit span forward 102 112 ‡
Digit span backward 63 72 ‡
Laboratory results
CSF A42, pg/mL 30761 505201 § §
CSF , pg/mL 940708 597298 §
CSF p-181 11064 8541 ‡
APOE 4: noncarriers 23% 32%
Heterozygous 46% 51%
Homozygous 31% 17%
Data are represented as meanSD unless indicated otherwise. Availability
for incomplete data for multiple MB patients: blood pressure measurements
17/21 mm Hg, MMSE, and VAT naming 18/21, VAT 19/21, animal fluency
17/21, Trail Making Test A 15/21, Trail Making Test B 11/21, APOE 13/21, CSF
9/21.
*Adjusted for WMH, MTA, age, and sex.
†P0.10.
‡P0.05.
§P0.01.
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this way, we aimed to maximize the supposed deleterious
effects associated with MBs and to increase the power to
demonstrate clinical correlates of MBs. In this way, we were
able to show that patients with AD with multiple MBs present
with more severe cognitive impairment. This finding could
not be explained by a more advanced disease stage as
illustrated by disease duration or degree of atrophy. Our
findings are in line with a recent study that showed a
relationship between number of MBs and cognitive impair-
ment in subcortical vascular dementia.18 Like our study, the
number of observed MBs was high (median number, 13). In
contrast with our study, patients were of Asian origin and
were diagnosed with subcortical vascular dementia, although
the authors mention that underlying Alzheimer pathology
could not be excluded.
The vast majority of MBs in our population was located in
lobar regions. The locations of MBs in our study are in line
with other studies that suggested CAA as underlying vascu-
lopathy of lobar MBs in AD.6,7,9,11,12 Only a small minority of
MBs was found in the basal ganglia, thalami, or infratentorial
regions. MBs in the deep gray matter structures have been
associated with vascular risk factors and hypertensive mi-
croangiopathy at autopsy.3,4,9,31,32 Furthermore, lobar MBs
have been associated with APOE 4 status in community-
based elderly population studies, whereas pure nonlobar MBs
lack an association with APOE 4.8,9 In our current study, the
relative prevalence of homozygous APOE 4 was nearly
twice as high in the multiple MB group as in the no MB
group, although the observed difference did not reach signif-
icance, probably due to lack of power. Moreover, when
patients with multiple deep MBs were excluded, the risk
became even higher. These findings support the notion that
strictly lobar MBs are indeed CAA-related and as a result
have a stronger association with homozygous APOE carrier-
ship. Remarkably, all homozygous 4 carriers with multiple
MBs had low WMH scores, seemingly suggesting separate
pathophysiological mechanisms for MBs presenting with and
without WMH.
Limitations of the study include the relatively small sample
size, cross-sectional design, and the retrospective nature of
the study. The retrospective design resulted in varying extent
of incomplete data. Furthermore, our ongoing efforts to
optimize the neuropsychological screening protocol have
resulted in a slightly varying order and content of the
neuropsychological evaluation during the years. We did not
account statistically for the missing data, in this way choosing
to stay close to the original data. We feel that given the
relatively large amount of missing data, imputation of miss-
ing data would potentially have added too much noise.
Furthermore, different scanners may have induced variabil-
ity in the results, because detection of MBs presumably
depends largely on imaging parameters.5 The most prominent
differences in MB detection, however, are reported on com-
paring images with postprocessing (ie, susceptibility-
weighted imaging) with regular T2*-weighted pulse se-
quences without postprocessing, varying echo times to a
greater extent than was the case in our study, and doubling of
field strengths, that is, 1.5 T versus 3 T. First, on all scanners,
T2*-weighted gradient-recalled echo was performed as op-
posed to susceptibility-weighted imaging that results in con-
siderably higher prevalence of MBs. Second, regarding scan-
ning parameters, slice thickness was constant on all
machines, interslice gaps were comparable (1 to 1.5 mm), flip
angle, and, most importantly, echo time were of comparable
order (22 to 25 ms) in our protocols. Finally, by matching for
field strength, we minimized the supposed effect of higher
field strengths. Moreover, field strengths did not include 3 T,
but only 1 and 1.5 T.
According to our proof-of-principle approach, we com-
pared patients with many MBs with patients without any MBs
to maximize supposed effects associated with MBs. Because,
to our knowledge, a firm definition of “many MBs” does not
exist, we had to use an arbitrary cutoff. We included the 5%
of patients with AD with the most severe MB burden with the
concomitant cutoff of 8 MBs. The main outcomes remained
unchanged, however, when we used 5 MBs or 10 MBs as
the cutoff, illustrating the robustness of our findings. These
findings must be confirmed in a larger cohort, ideally pathol-
ogy confirmed, including patients with AD with one or a few
MBs to answer the question whether our findings are specific
for the small subgroup of patients with AD with many MBs
or that there is a dose–response relationship with patients
with one or a few MBs being in between. The critical
question raised by these findings is whether MBs are part of
a spectrum of abnormalities in AD or reflect a distinct
pathological subgroup.
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